Different effects of angiotensin ii and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Zhang, Feng ^a,b   Hu, Yanhua ^c   Xu, Qingbo ^c   Ye, Shu ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; 7 ALA ANGIOTENSIN (1 7); 7-ALA-ANGIOTENSIN (1-7); ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); DRUG DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDE FRAGMENT;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; INCUBATION TIME; MOUSE; NONHUMAN; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL MOTION; CYTOLOGY; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 77957881110     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012323     Document Type: Article

References (52)

1. Lusis AJ (2000) Atherosclerosis. Nature 407: 233-241.
2. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, et al. (1991) Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253: 1129-1132.
3. Weiss D, Sorescu D, Taylor WR (2001) Angiotensin II and atherosclerosis. Am J Cardiol 87: 25C-32C.
4. Touyz RM, Schiffrin EL (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672.
5. Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, et al. (1999) Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19: 73-82.
6. Lee HM, Lee CK, Lee SH, Roh HY, Bae YM, et al. (2007) p38 mitogenactivated protein kinase contributes to angiotensin II-stimulated migration of rat aortic smooth muscle cells. J Pharmacol Sci 105: 74-81.
7. Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, et al. (2005) Signalcrosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol 25: 1831-1836.
8. Yang X, Zhu MJ, Sreejayan N, Ren J, Du M (2005) Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparinbinding epidermal growth factor and activation of EGF-receptor pathway. Mol Cells 20: 263-270.
9. Kyaw M, Yoshizumi M, Tsuchiya K, Kagami S, Izawa Y, et al. (2004) Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol 65: 832-841.
10. Mugabe BE, Yaghini FA, Song CY, Buharalioglu CK, Waters CM, et al. (2009) Angiotensin II-induced migration of vascular smooth muscle cells is mediated by p38 mitogen-activated protein kinase-activated c-Src through spleen tyrosine kinase and epidermal growth factor receptor transactivation. J Pharmacol Exp Ther 332: 116-124.
11. Touyz RM, Deng LY, He G, Wu XH, Schiffrin EL (1999) Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens 17: 907-916.
12. Keidar S, Kaplan M, Gamliel-Lazarovich A (2007) ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 73: 463-469.
13. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, et al. (2008) Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319-1326.
14. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-8263.
15. Souza Dos Santos RA, Passaglio KT, Pesquero JB, Bader M, Simoes ESAC (2001) Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension 38: 660-664.
16. Tallant EA, Clark MA (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42: 574-579.
17. Su Z, Zimpelmann J, Burns KD (2006) Angiotensin-(1-7) inhibits angiotensin IIstimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69: 2212-2218.
18. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM (2007) Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 50: 1093-1098.
19. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28: 104-108.
20. Langeveld B, van Gilst WH, Tio RA, Zijlstra F, Roks AJ (2005) Angiotensin-(1- 7) attenuates neointimal formation after stent implantation in the rat. Hypertension 45: 138-141.
21. Tallant EA, Diz DI, Ferrario CM (1999) State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34: 950-957.
22. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM (1991) Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68: 450-456.
23. Gallagher PE, Tallant EA (2004) Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25: 2045-2052.
24. Tallant EA, Ferrario CM, Gallagher PE (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-1566.
25. Zhang J, Noble NA, Border WA, and Huang Y. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 298: F579-588.
26. Zeng W, Chen W, Leng X, He JG, Ma H (2009) Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun 389: 138-144.
27. Strawn WB, Ferrario CM, Tallant EA (1999) Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33: 207-211.
28. Wang Y, Qian C, Roks A, Westermann D, Schumacher SM, et al. Circulating Rather than Cardiac Angiotensin-(1-7) Stimulates Cardioprotection Post Myocardial Infarction. Circ Heart Fail).
29. Heringer-Walther S, Eckert K, Schumacher SM, Uharek L, Wulf-Goldenberg A, et al. (2009) Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 94: 857-860.
30. Yoshida O, Hirayama H, Nanasato M, Watanabe T, Murohara T (2005) The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J 149: e2.
31. Hu Y, Cheng L, Hochleitner BW, Xu Q (1997) Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 17: 2808-2816.
32. Izumi Y, Kim S, Namba M, Yasumoto H, Miyazaki H, et al. (2001) Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in ballooninjured rat artery. Circ Res 88: 1120-1126.
33. Hunger-Glaser I, Salazar EP, Sinnett-Smith J, Rozengurt E (2003) Bombesin, lysophosphatidic acid, and epidermal growth factor rapidly stimulate focal adhesion kinase phosphorylation at Ser-910: requirement for ERK activation. J Biol Chem 278: 22631-22643.
34. Liu ZX, Yu CF, Nickel C, Thomas S, Cantley LG (2002) Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillinfocal adhesion kinase association. J Biol Chem 277: 10452-10458.
35. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56-68.
36. Pan CH, Wen CH, Lin CS (2008) Interplay of angiotensin II and angiotensin(1- 7) in the regulation of matrix metalloproteinases of human cardiocytes. Exp Physiol 93: 599-612.
37. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, et al. (2002) Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 91: 852-859.
38. Cho A, Graves J, Reidy MA (2000) Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20: 2527-2532.
39. Sharony R, Pintucci G, Saunders PC, Grossi EA, Baumann FG, et al. (2006) Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2. Am J Physiol Heart Circ Physiol 290: H1651-1659.
40. Brosnihan KB, Li P, Ferrario CM (1996) Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523-528.
41. Heitsch H, Brovkovych S, Malinski T, Wiemer G (2001) Angiotensin-(1-7)- Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells. Hypertension 37: 72-76.
42. Dubey RK, Jackson EK, Luscher TF (1995) Nitric oxide inhibits angiotensin IIinduced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 96: 141-149.
43. Clark MA, Diz DI, Tallant EA (2001) Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension 37: 1141-1146.
44. Bovy PR, Trapani AJ, McMahon EG, Palomo M (1989) A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists. J Med Chem 32: 520-522.
45. Ueda S, Masumori-Maemoto S, Ashino K, Nagahara T, Gotoh E, et al. (2000) Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35: 998-1001.
46. Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, et al. (1999) Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 34: 296-301.
47. Ueda S, Masumori-Maemoto S, Wada A, Ishii M, Brosnihan KB, et al. (2001) Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. J Hypertens 19: 2001-2009.
48. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, et al. (2007) Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-742.
49. Hu Y, Zou Y, Dietrich H, Wick G, Xu Q (1999) Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation 100: 861-868.
50. Burson JM, Aguilera G, Gross KW, Sigmund CD (1994) Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol 267: E260-267.
51. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.
52. Li C, Wernig F, Leitges M, Hu Y, Xu Q (2003) Mechanical stress-activated PKCdelta regulates smooth muscle cell migration. Faseb J 17: 2106-2108.